Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$43.0555
-0.91(-2.1%)
as of December 19, 2025
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
43.0555
Open
42.1486
High
43.6954
Low
41.6897
52 wk Range
17.82-43.7306
Market Cap
3 274 M
P/E Ratio
95.9778
Shares Outstanding
45 161 K
Revenue
598 M
EPS
0.23
Beta
0.014
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 598 M
- EBITDA: 39 641 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-04
- EPS/Forecast: 0.3139
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
High Growth Tech Stocks To Watch In The US December 2025
As the U.S. market navigates a complex landscape marked by rising unemployment and mixed performances across major indices, the tech-heavy Nasdaq managed to tick higher, snapping a losing streak amid ...
US High Growth Tech Stocks To Watch December 2025
As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sec...
US High Growth Tech Stocks to Watch
The United States market has recently experienced declines in major stock indexes, with technology shares exerting downward pressure on the Nasdaq amid concerns about an AI bubble. In this environment...
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool. DATE Oct. 28, 2025 at 11:41 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Sanj PatelChief Commercial Officer — Ross MoatChief Financial Office...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
